GoodRx (NASDAQ:GDRX) Misses Q4 Revenue Estimates
Healthcare tech company GoodRx (NASDAQ:GDRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $198.6 million. On the other hand, the company expects next quarter’s revenue to be around $203 million, close to analysts’ estimates. Its non-GAAP profit of $0.09 per share was in line with analysts’ consensus estimates.